Moonlake logo.png
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
July 26, 2022 08:00 ET | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics AG (MoonLake; Nasdaq:...
AMR Logo.png
Global Monoclonal Antibodies Market is Expected to Reach $390.58 Billion by 2030: Says AMR
July 20, 2021 08:34 ET | Allied Market Research
Portland, OR, July 20, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Monoclonal Antibodies Market was estimated at $146.64 billion in 2020 and is...
180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics
March 26, 2021 08:30 ET | 180 Life Sciences Corp.
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.” ...
Reports and Data.jpeg-01
Infusion Therapy Market To Reach USD 10.98 Billion By 2027 | Reports and Data
March 11, 2020 11:00 ET | Reports and Data
New York, March 11, 2020 (GLOBE NEWSWIRE) -- The Global Infusion therapy market is forecast to reach USD 10.98 Billion by 2027, according to a new report by Reports and Data. Infusion therapy is...
Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment Market to Witness CAGR of 6.3% during 2018– 2024: Energias Market Research Pvt. Ltd.
March 23, 2018 07:00 ET | Energias Market Research
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment market size is expected to reach, USD 153.5 Billion in 2024, at a CAGR of 6.3% from 2018...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
June 08, 2015 21:12 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
May 12, 2015 05:08 ET | Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...
Rafarma Pharmaceuticals, Inc. logo
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
June 06, 2013 09:18 ET | Rafarma Pharmaceuticals, Inc.
SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone. Ceftriaxone treats...